All In Biotech

Drug Trial Radar · NCT05792163

A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of SNP318 in Healthy Adult Participants

Last checked: Nov 19, 2026Latest source record: Dec 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

76

Actual

Start

Mar 20, 2023

Primary completion

Nov 29, 2023

Study completion Nov 29, 2023

Sponsor

Lead sponsor
SciNeuroIndustry
Sponsor type
Industry
First posted
Mar 31, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

SNP318 is developed to treat neurodegenerative diseases including Alzheimer's disease. In the current phase 1 study, the IP is tested in healthy volunteers, and the purpose is to investigate the safety, tolerability, and PK of single and multiple ascending oral doses of SNP318.

Conditions

  • Neurodegenerative Diseases
  • Alzheimer's Disease

Interventions

  • SNP318 (A)Drug

    Capsule for oral administration

  • Placebo (B)Drug

    Placebo capsules matching the SNP318 capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of SNP318 in healthy adult participants. Assessed by adverse eventsTime frame: Up to 20 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CMAX Clinical Research

    Adelaide, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.